Devonian Health Group Inc. (CVE:GSD – Get Free Report) was down 10.3% on Thursday . The company traded as low as C$10.00 and last traded at C$10.00. Approximately 1,800 shares changed hands during mid-day trading, an increase of 50% from the average daily volume of 1,201 shares. The stock had previously closed at C$11.15.
Devonian Health Group Price Performance
The business has a 50 day moving average price of C$11.09 and a two-hundred day moving average price of C$11.77. The stock has a market cap of C$29.20 million, a PE ratio of -3.03 and a beta of 0.46. The company has a debt-to-equity ratio of 16.36, a quick ratio of 7.82 and a current ratio of 1.07.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
Featured Articles
- Five stocks we like better than Devonian Health Group
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
